保存超过12小时的肺移植后结局:一项回顾性研究
该研究回顾了2006年1月1日至2015年4月30日期间在加拿大多伦多单家医院接受肺移植的906例患者,按总保存时间分为>12小时组(n=97,平均875.7分钟)和<12小时组(n=809,平均400.8分钟)。总保存时间定义为首次冷缺血时间、EVLP时间和第二次冷缺血时间之和。主要结局为生存率和移植后72小时原发性移植物功能障碍(PGD)分级。结果显示两组住院时长、ICU时长、PGD分级及生存率均无显著差异(p值分别为0.60、0.53、0.85、0.61)。多变量Cox模型显示受者年龄增加是影响生存的显著变量。作者认为,通过EVLP将移植物保存时间延长至超过12小时不会对早期肺移植结局产生负面影响,并可能通过改善手术时间安排的灵活性而增加移植数量。
要点
- 在单中心回顾性研究中,>12小时保存组(n=97,平均875.7分钟)与<12小时组(n=809,平均400.8分钟)的住院时长(23天 vs 25.5天,p=0.60)和ICU时长(4天 vs 4天,p=0.53)无显著差异。
- 两组移植后72小时PGD分级无差异(p=0.85),Kaplan-Meier生存曲线无差异(p=0.61)。
- 多变量Cox模型显示,受者年龄增加是影响生存的显著变量。
- 作者认为,通过EVLP将临床肺保存时间延长至超过12小时不会对早期肺移植结局产生负面影响,并可能因改善手术时间安排的灵活性而增加移植数量。
适用人群与场景
- 2006年1月1日至2015年4月30日在加拿大多伦多单家医院接受至少一次肺移植的患者。
- 排除接受心肺联合移植或年龄小于18岁的患者。
- 双侧肺移植时,取两肺中较长的保存时间进行分析。
诊断标准与关键阈值
- 总保存时间定义为首次冷缺血时间、EVLP时间和第二次冷缺血时间之和。
- 以总保存时间>12小时和<12小时分组。
- 肺保存按现行标准治疗进行,EVLP按多伦多EVLP技术进行。
研究设计与关键结果
- 研究类型:回顾性研究,纳入906例患者(<12小时组n=809,平均肺保存时间400.8分钟[SD 121.8];>12小时组n=97,平均875.7分钟[SD 109.0])。
- 主要结局:>12小时组与<12小时组的住院时长(23天[16-42] vs 25.5天[17-50.25],p=0.60)和ICU时长(4天[2-14] vs 4天[2-16],p=0.53)相似。
- 移植后72小时PGD分级两组无差异(p=0.85);Kaplan-Meier生存曲线显示两组生存无差异(p=0.61)。
- 多变量Cox生存分析显示,受者年龄增加是影响生存的显著变量。
证据类型、等级与局限
- 证据类型:回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,通过EVLP将临床肺保存时间延长至超过12小时不会对早期肺移植结局产生负面影响;延长临床肺保存时间可能因改善手术时间安排的便利性和增加灵活性而使更多移植得以进行。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ex-vivo lung perfusion (EVLP) can be used to extend overall lung preservation time by splitting one long cold ischaemic time into two shorter ones and interposing an additional EVLP time. We assessed the outcomes after clinical transplantation of lungs with more than 12 h of preservation time.
METHODS: For this retrospective study, we searched the Toronto Lung Transplant Program database for patients who had received at least one lung transplant between Jan 1, 2006, and April 30, 2015, at a single hospital in Toronto, Canada. We split the identified patients into those with a total preservation time of more than 12 h and those with a total preservation time of less than 12 h to act as the control group. Total preservation time was defined as the sum of first cold ischaemic time, EVLP time, and second cold ischaemic time. We excluded patients if they had received a heart-lung transplant or were younger than 18 years. In bilateral lung transplantations, we used the longer preservation time of the two lungs for analysis. Lung preservation was done according to present standards of care and EVLP was done according to the Toronto EVLP technique. The primary outcomes were survival and International Society for Heart and Lung Transplantation Primary Graft Dysfunction (PGD) grade at 72 h post-transplantation. We compared outcomes with our control group using univariable and multivariable models.
FINDINGS: We identified 906 patients who met eligibility criteria and had sufficient data for analysis (<12 h group [n=809]; mean lung preservation time 400·8 min [SD 121·8] vs >12 h group [n=97]; 875·7 min [109·0]). Median hospital and intensive-care unit length of stay were similar between the less than 12 h group and the more than 12 h group (hospital stay: 23 days [16-42] vs 25·5 days [17-50·25], p=0·60; intensive-care unit stay: 4 days [2-14] vs 4 days [2-16], p=0·53). PGD grade was also not different between the two groups at 72 h post-transplantation (p=0·85). There was also no difference in survival between the two groups as shown on Kaplan-Meier survival curves (p=0·61). Multivariable survival analysis using Cox's model showed increasing recipient age to be a significant variable affecting survival.
INTERPRETATION: Extension of graft preservation time beyond 12 h with EVLP does not negatively affect early lung transplantation outcomes. Extension of clinical lung preservation times might allow for more transplantations to be done as a result of improved facilitation and increased flexibility around timing of lung transplantation operations.
参考来源
- Yeung JC, Krueger T, Yasufuku K, et al. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. Lancet Respir Med. 2016. PMID: 27866861. doi:10.1016/S2213-2600(16)30323-X
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。